Physical exercise, the immune system and infection risk: implications for prehabilitation and rehabilitation for solid organ transplantation candidates and recipients DOI
Nicolette C. Bishop

Current Opinion in Organ Transplantation, Год журнала: 2024, Номер 29(4), С. 271 - 276

Опубликована: Июнь 7, 2024

Purpose of review Solid organ transplantation recipients have an increased risk infection, exacerbated by immunosuppressant medications that need to finely balance suppression the immune system prevent allograft rejection while avoiding over-suppression leading infections and malignancy. Exercise modulates functions, with moderate-intensity activities particularly associated enhanced antiviral immunity reduced infection incidence. However, investigations effects exercise physical activity on function posttransplantation are scarce. This highlights areas where relationship between exercise, has greatest potential for benefit solid therefore investigation. Recent findings Moderate higher intensity do not appear cause adverse immunological in kidney recipients, although evidence from other is lacking. Evidence healthy younger older adults suggests regular can reduce respiratory latent herpesvirus reactivation improves antibody responses vaccination, which great importance recipients. Summary There a strong research investigate role improve both survival long-term health recipient.

Язык: Английский

The Time-Dependent Association of Torque Teno Virus Load with the Level of SARS-CoV-2 S1 IgG Antibodies Following COVID-19 Vaccination in Kidney Transplant Recipients DOI Creative Commons
Céline Imhof, A. Lianne Messchendorp, Debbie van Baarle

и другие.

Viruses, Год журнала: 2023, Номер 15(11), С. 2189 - 2189

Опубликована: Окт. 31, 2023

Kidney transplant recipients (KTR) show an impaired humoral immune response to COVID-19 vaccination due their immunocompromised status. Torque teno virus (TTV) is a possible marker of function. This may be helpful in predicting the after order decide which strategy should applied. We therefore investigated whether TTV load associated with vaccination. Of KTR who participated two prospective studies and received four doses mRNA-1273 vaccine, 122 were included. was measured prior vaccination, S1 IgG antibody levels 28 days independently inversely antibodies (B: −2.19 (95% CI: −3.6–−0.8), p = 0.002). Interestingly, we found significant interaction between time transplantation (p 0.005). When patients longer transplantation, less predictive for compared that shorter transplantation. Our data suggest good selecting shortly However, this handled caution

Язык: Английский

Процитировано

4
Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients DOI Creative Commons
Dharmendra Bhadauria,

Harshita Katiyar,

Amit Goel

и другие.

Vaccines, Год журнала: 2022, Номер 10(10), С. 1693 - 1693

Опубликована: Окт. 11, 2022

Kidney transplant recipients (KTRs) are at a much higher risk of complications and death following COVID-19 poor vaccine responders. The data limited on the immune response to Covishield® in KTRs. We prospectively recruited cohort 67 KTRs aged >18 between April 2021 December 2021. Each participant was given two intramuscular doses Covishield®, each 0.5 mL, an interval 12 weeks. A blood specimen 5.0 mL collected from points within few days before administering first dose any time 4−12 weeks after second dose. sera were tested for anti-RBD antibody (ARAb) titre neutralising (NAb). An ACE2 competition assay used as proxy virus neutralization. According prior infection, participants grouped (i) group A: symptomatic (ii) B: asymptomatic infection evidenced by detectable ARAb prevaccination specimen, (iii) Group C: no with COVID-19, (iv) D: Unclassified, i.e., had symptoms suggestive but their not available testing vaccination. Fifty sixty-seven (74.6%) provided paired specimens (group 14, B 27, C 9) 17 (25.4%) only postvaccination D). In overall (n = 67), 91% 77.6% developed NAb, respectively. Their NAb proportion 2927 (520−7124) U/mL 87.9 (24.4−93.2) %, median increased 65.6 folds, 38.2 3137 U/mL. Similarly, 56% 86%, raised 2.7 23% 91%. comparison study groups showed that all those or without significant rise (p < 0.05) administration. value folds comparable. Hence, is present more than 3/4th ChAdOx1 India. titer significantly

Язык: Английский

Процитировано

7
COVID-19 in Lung Transplant Recipients: A Report on 10 Recent Cases DOI Creative Commons

Lea Reemann,

Nikolaus Kneidinger,

B Sczepanski

и другие.

Viruses, Год журнала: 2024, Номер 16(5), С. 709 - 709

Опубликована: Апрель 29, 2024

Due to immunosuppression, transplant recipients are at higher risk of infections with SARS-CoV-2 and worse clinical outcomes than immunocompetent hosts. Furthermore, lung patients represent a special group among solid organ recipients, since pneumonia is the main manifestation COVID-19. However, data on course disease changes in morbidity mortality during pandemic limited. In our pulmonary rehabilitation clinic, we treat shortly after as well long-term patients. Over last almost 4 years pandemic, witnessed several COVID-19 clinic who acquired an infection beforehand. this paper, aim retrospectively describing series recent cases looking

Язык: Английский

Процитировано

1
COVID-19 Vaccine in Lung and Liver Transplant Recipients Exceeds Expectations: An Italian Real-Life Experience on Immunogenicity and Clinical Efficacy of BNT162b2 Vaccine DOI Creative Commons
Letizia Corinna Morlacchi, Gianfranco Alicandro, Sara Uceda Renteria

и другие.

Transplant International, Год журнала: 2024, Номер 37

Опубликована: Июль 10, 2024

This study assessed humoral and T cell-mediated immune responses to the BNT162b2 vaccine in orthotopic liver transplant (OLT) lung (LUT) recipients who received three doses of from March 2021 at our institution. Serum samples were collected 60 days post-second third dose quantify antibodies against spike region SARS-CoV-2 while whole blood analyze SARS-CoV-2-specific T-cell response using an IFN-γ ELISpot assay. We enrolled 244 OLT 120 LUT recipients. The increased antibody titres (from a median value 131 after second 5523 IU/mL,

Язык: Английский

Процитировано

1
COVID-19 vaccine updates for people under different conditions DOI

Yi-Jiao Huang,

Weiyang Wang, Yan Liu

и другие.

Science China Life Sciences, Год журнала: 2024, Номер 67(11), С. 2323 - 2343

Опубликована: Июль 29, 2024

Язык: Английский

Процитировано

1
Hybrid Immunity Overcomes Defective Immune Response to COVID-19 Vaccination in Kidney Transplant Recipients DOI Creative Commons
Nicolas Gemander, Delphine Kemlin, Stéphanie Depickère

и другие.

Kidney International Reports, Год журнала: 2023, Номер 9(3), С. 635 - 648

Опубликована: Дек. 20, 2023

IntroductionComorbidities and immunosuppressive therapies are associated with reduced immune responses to primary COVID-19 mRNA vaccination in kidney transplant recipients (KTRs). In healthy individuals, prior SARS-COV-2 infection is increased vaccine responses, a phenotype called hybrid immunity. this study, we explored the potential influence of suppression on immunity KTRs.MethodsEighty-two KTRs, including 59 SARS-CoV-2-naive 23 SARS-CoV-2-experienced patients, were prospectively studied compared 106 controls (HCs), 40 66 subjects. Polyfunctional antibody T cell measured following two doses BNT162b2 vaccine. Associations between clinical characteristics by univariate multivariate analyses.ResultsIn naive markedly lower than HCs correlated older age, more recent transplantation, retransplantation after graft failure, arterial hypertension, treatment mycophenolate mofetil (MMF). contrast, KTRs similar those time transplantation vaccination, but not other risk factors low KTRs.ConclusionIn conclusion, overcomes provides potent humoral cellular SARS-CoV-2 KTRs.

Язык: Английский

Процитировано

3
Immunogenicity, Immune Dynamics, and Subsequent Response to the Booster Dose of Heterologous versus Homologous Prime-Boost Regimens with Adenoviral Vector and mRNA SARS-CoV-2 Vaccine among Liver Transplant Recipients: A Prospective Study DOI Creative Commons
Supachaya Sriphoosanaphan,

Sirinporn Suksawatamnuay,

Nunthiya Srisoonthorn

и другие.

Vaccines, Год журнала: 2022, Номер 10(12), С. 2126 - 2126

Опубликована: Дек. 12, 2022

Background: Heterologous prime-boost vaccination potentially augments the immune response against SARS-CoV-2 in liver transplant (LT) recipients. We investigated immunogenicity induced by different primary protocols and subsequent to booster vaccine among LT Methods: recipients, who received immunisation with ChAdOx1/ChAdOx1 or ChAdOx1/BNT162b2, were administered third dose of mRNA-1273 three months following vaccination. Blood samples collected before after post-booster. The levels receptor binding domain antibody (anti-RBD) neutralising (sVNT) spike-specific T-cell responses assessed. Results: Among 89 patients receiving ChAdOx1/BNT162b2 had significantly higher anti-RBD titres, sVNT, cellular than those (p < 0.05). decreased 12 weeks After booster, humoral improved, comparable seroconversion rates between heterologous homologous groups. Positive sVNT wild type occurred >90% patients, only 12.3% positive Omicron variant. Conclusions: evoked a immunological strategy substantially robust immunity most but was less effective strain.

Язык: Английский

Процитировано

4
COVID-19 in solid organ transplant recipients after 2 years of pandemic: Outcome and impact of antiviral treatments in a single-center study DOI Creative Commons
Biagio Pinchera, Antonio Riccardo Buonomo,

Emilia Trucillo

и другие.

Frontiers in Transplantation, Год журнала: 2023, Номер 2

Опубликована: Март 16, 2023

More than 2 years after the pandemic, availability of vaccination and use monoclonal antibodies direct antivirals have changed fate COVID-19, allowing for a better management disease, reducing hospitalization rates, improving survival. This study aims to describe outcome COVID-19 in cohort solid organ transplant recipients impact novel against SARS-CoV-2. We conducted an observational retrospective study. enrolled with attending A.O.U. Federico II Naples followed up from January 2022 July 2022. 40 SOTs COVID-19. Our experience highlights favorable therapies early stages Interesting data concern immunosuppressive therapy on particular role Mycophenolate (associated deterioration severe COVID-19) Everolimus (protective progression disease) needs be investigated. also confirms fundamental importance booster dose.

Язык: Английский

Процитировано

2
Measures to Increase Immunogenicity of SARS-CoV-2 Vaccines in Solid Organ Transplant Recipients: A Narrative Review DOI Creative Commons
Bo Yu, Christina Tamargo, Daniel C. Brennan

и другие.

Vaccines, Год журнала: 2023, Номер 11(12), С. 1755 - 1755

Опубликована: Ноя. 25, 2023

Purpose of review: To review the data on immunogenicity COVID-19 vaccines, administered by different strategies, in solid organ transplant recipients (SOTRs). Recent findings: booster vaccines were given to SOTRs as a widespread practice many centers, mostly third and/or fourth dose an extended vaccine series, with significantly improved humoral response compared initial two-dose scheme. However, one-third remained unresponsive, despite these boosters. Next steps: Vaccination standard dosing remains most feasible strategy for attaining protection against COVID-19. Additional doses and temporarily holding or reducing mycophenolate mofetil/mycophenolic acid may provide according recent studies demonstrating some efficacy measures. Preexposure prophylaxis monoclonal antibodies showed benefit immunocompromised patients but is no longer recommended National Institutes Health (NIH) due diminished Omicron variants. Screening presence titers SARS-CoV-2-specific not clinical settings. T cell-based techniques are needed evaluate risk infection. As SARS-CoV-2 continues evolve, new based conservative protein component/complexes COVID virus, addition its spike protein, warranted offer prolonged protection.

Язык: Английский

Процитировано

2
Central Nervous System Neuroimmunologic Complications of COVID-19 DOI
Kathryn B. Holroyd, Sarah Conway

Seminars in Neurology, Год журнала: 2023, Номер 43(02), С. 229 - 250

Опубликована: Апрель 1, 2023

Autoimmune disorders of the central nervous system following COVID-19 infection include multiple sclerosis (MS), neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, autoimmune encephalitis, acute disseminated encephalomyelitis, and other less common neuroimmunologic disorders. In general, these are rare likely represent postinfectious phenomena rather than direct consequences SARS-CoV-2 virus itself. The impact on patients with preexisting neuroinflammatory depends both disorder disease-modifying therapy use. Patients MS do not have an increased risk for severe COVID-19, though anti-CD20 therapies may worse clinical outcomes attenuated humoral response to vaccination. Data limited disorders, but known factors such as older age medical comorbidities play a role. Prophylaxis treatment should be considered in at high developing COVID-19.

Язык: Английский

Процитировано

1